Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
FiercePharma4d
JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...
FiercePharma10d
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
FierceBiotech4d
JPM25, Day 2: Pharma should 'run towards' vaccine efficacy conversations, says GSK CEO
Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
BioPharma Dive10d
FDA adds warning to RSV shots from GSK, Pfizer
Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.
Reuters11d
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...